AI Tokens
Stock Analysis on Net

Elevance Health Inc. (NYSE:ELV)

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Solvency Ratios (Summary)

Debt Ratios

Coverage Ratios

Elevance Health Inc., solvency ratios (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Debt Ratios
Debt to equity 0.69 0.69 0.73 0.73 0.73 0.69 0.71 0.76 0.62 0.66 0.65 0.64 0.65 0.66 0.68 0.66 0.66 0.66 0.65
Debt to capital 0.41 0.41 0.42 0.42 0.42 0.41 0.41 0.43 0.38 0.40 0.39 0.39 0.39 0.40 0.41 0.40 0.40 0.40 0.39
Debt to assets 0.24 0.25 0.25 0.26 0.26 0.25 0.25 0.27 0.23 0.25 0.24 0.23 0.22 0.23 0.23 0.23 0.23 0.23 0.23
Financial leverage 2.86 2.82 2.87 2.77 2.79 2.79 2.82 2.83 2.66 2.68 2.76 2.77 2.88 2.86 2.92 2.83 2.86 2.82 2.79
Coverage Ratios
Interest coverage 5.33 5.08 5.39 5.79 6.16 6.33 7.14 7.67 8.52 9.07 8.70 8.49 8.87 9.76 9.95 10.13 10.75 10.71 11.01

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The solvency profile exhibits a generally stable capital structure characterized by consistent leverage ratios, though a significant and sustained decline in the ability to cover interest expenses is evident over the observed period.

Debt-to-Equity and Debt-to-Capital Ratios
The debt-to-equity ratio remained relatively stable between 0.64 and 0.68 from March 2022 through September 2023. A notable increase occurred toward the end of 2024, peaking at 0.76 in December 2024 before stabilizing around 0.69 to 0.73 in 2025 and 2026. Similarly, the debt-to-capital ratio maintained a tight range around 0.39 to 0.41, with a corresponding peak of 0.43 in December 2024, suggesting a marginal increase in the proportion of debt relative to total capital.
Debt-to-Assets Ratio
The proportion of assets financed by debt remained highly consistent, hovering between 0.22 and 0.25 for the majority of the period. A temporary increase to 0.27 was recorded in December 2024, aligned with the peaks seen in other debt ratios, followed by a return to a range of 0.24 to 0.26 through September 2026.
Financial Leverage
Financial leverage demonstrated a non-linear pattern, oscillating between a low of 2.66 in September 2024 and a high of 2.92 in March 2023. The ratio shows no long-term upward or downward trend, indicating that the overall multiplier effect of the company's asset base relative to equity has remained constant.
Interest Coverage Ratio
A pronounced downward trend is observed in the interest coverage ratio, which declined from 11.01 in March 2022 to 5.33 by September 2026. The degradation was gradual throughout 2022 and 2023, accelerating through 2024 and 2025. This consistent decline indicates a reduction in the margin of safety for meeting interest obligations, suggesting either an increase in debt servicing costs or a contraction in operating earnings.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Debt to Equity

Elevance Health Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Short-term borrowings — — 724 150 180 360 250 365 360 225 1,575 225 — 265 265 265 265 175 275
Current portion of long-term debt 375 375 350 1,099 749 1,648 1,643 1,649 2,100 2,900 2,900 1,649 799 — — 1,500 2,249 2,248 3,097
Long-term debt, less current portion 30,382 30,669 30,768 30,797 31,173 28,178 28,110 29,218 24,688 24,561 21,976 23,246 24,045 24,859 25,201 22,349 21,258 21,165 19,883
Total debt 30,757 31,044 31,842 32,046 32,102 30,186 30,003 31,232 27,148 27,686 26,451 25,120 24,844 25,124 25,466 24,114 23,772 23,588 23,255
 
Shareholders’ equity 44,681 44,883 43,902 43,882 43,953 43,722 42,503 41,315 43,775 42,191 40,608 39,306 38,423 38,205 37,356 36,307 35,991 35,812 35,975
Solvency Ratio
Debt to equity1 0.69 0.69 0.73 0.73 0.73 0.69 0.71 0.76 0.62 0.66 0.65 0.64 0.65 0.66 0.68 0.66 0.66 0.66 0.65
Benchmarks
Debt to Equity, Competitors2
Abbott Laboratories 0.61 0.64 0.65 0.25 0.25 0.27 0.27 0.30 0.38 0.38 0.38 0.38 0.41 0.45 0.46 0.46 0.46 0.46 0.48
Intuitive Surgical Inc. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Medtronic PLC 0.57 0.60 0.60 0.59 0.54 0.58 0.58 0.50 0.49 0.49 0.49 0.47 0.55 0.51 0.44 0.46 0.48 0.49 0.50
UnitedHealth Group Inc. 0.76 0.74 0.80 0.83 0.84 0.84 0.86 0.83 0.83 0.84 0.85 0.70 0.75 0.80 0.87 0.74 0.65 0.71 0.65

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= 30,757 ÷ 44,681 = 0.69

2 Click competitor name to see calculations.


The solvency profile demonstrates a general increase in leverage over the analyzed period, characterized by a steady expansion of both total debt and shareholders' equity, with a notable period of volatility observed in late 2024.

Total Debt Trends
Total debt exhibited a gradual increase from 23,255 million USD in March 2022 to 25,120 million USD by December 2023. A significant acceleration in borrowing occurred throughout 2024, with total debt peaking at 31,232 million USD in December 2024. Following this peak, debt levels remained elevated, fluctuating between 30,003 million USD and 32,102 million USD throughout 2025, before trending slightly downward to 30,757 million USD by September 2026.
Shareholders' Equity Growth
Equity showed a consistent long-term upward trajectory, rising from 35,975 million USD in March 2022 to 44,681 million USD by September 2026. A temporary contraction was observed in December 2024, where equity decreased to 41,315 million USD, marking a deviation from the general growth trend before resuming an upward climb in 2025.
Debt to Equity Ratio Analysis
The debt to equity ratio remained relatively stable, fluctuating between 0.64 and 0.68 from March 2022 through March 2024. A peak ratio of 0.76 was reached in December 2024, directly correlating with the simultaneous increase in total debt and the dip in shareholders' equity. In the subsequent periods from 2025 through September 2026, the ratio established a new baseline, oscillating between 0.69 and 0.73, indicating a sustained increase in financial leverage compared to the 2022-2023 period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Debt to Capital

Elevance Health Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Short-term borrowings — — 724 150 180 360 250 365 360 225 1,575 225 — 265 265 265 265 175 275
Current portion of long-term debt 375 375 350 1,099 749 1,648 1,643 1,649 2,100 2,900 2,900 1,649 799 — — 1,500 2,249 2,248 3,097
Long-term debt, less current portion 30,382 30,669 30,768 30,797 31,173 28,178 28,110 29,218 24,688 24,561 21,976 23,246 24,045 24,859 25,201 22,349 21,258 21,165 19,883
Total debt 30,757 31,044 31,842 32,046 32,102 30,186 30,003 31,232 27,148 27,686 26,451 25,120 24,844 25,124 25,466 24,114 23,772 23,588 23,255
Shareholders’ equity 44,681 44,883 43,902 43,882 43,953 43,722 42,503 41,315 43,775 42,191 40,608 39,306 38,423 38,205 37,356 36,307 35,991 35,812 35,975
Total capital 75,438 75,927 75,744 75,928 76,055 73,908 72,506 72,547 70,923 69,877 67,059 64,426 63,267 63,329 62,822 60,421 59,763 59,400 59,230
Solvency Ratio
Debt to capital1 0.41 0.41 0.42 0.42 0.42 0.41 0.41 0.43 0.38 0.40 0.39 0.39 0.39 0.40 0.41 0.40 0.40 0.40 0.39
Benchmarks
Debt to Capital, Competitors2
Abbott Laboratories 0.38 0.39 0.40 0.20 0.20 0.21 0.21 0.23 0.27 0.27 0.27 0.28 0.29 0.31 0.31 0.31 0.32 0.31 0.33
Intuitive Surgical Inc. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Medtronic PLC 0.36 0.37 0.37 0.37 0.35 0.37 0.37 0.33 0.33 0.33 0.33 0.32 0.35 0.34 0.31 0.31 0.32 0.33 0.34
UnitedHealth Group Inc. 0.43 0.43 0.44 0.45 0.46 0.46 0.46 0.45 0.45 0.46 0.46 0.41 0.43 0.44 0.46 0.43 0.39 0.41 0.39

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= 30,757 ÷ 75,438 = 0.41

2 Click competitor name to see calculations.


The solvency profile reflects a period of steady expansion in both total debt and total capital from March 2022 through September 2026. While absolute liabilities increased significantly over the timeframe, the capital structure remained balanced, maintaining a relatively stable leverage ratio.

Total Debt Trends
A consistent upward trajectory in total debt is observed, rising from 23,255 million US dollars in March 2022 to a peak of 32,102 million US dollars in September 2025. A notable acceleration in borrowing occurred between September 30, 2024, and December 31, 2024, during which total debt increased by approximately 4,084 million US dollars. Following this peak, debt levels entered a period of slight contraction, ending at 30,757 million US dollars by September 30, 2026.
Total Capital Growth
Total capital exhibited a sustained increase, growing from 59,230 million US dollars to 75,438 million US dollars over the analyzed period. This growth in the capital base occurred almost concurrently with the increase in debt, suggesting a strategic expansion of the balance sheet to support operational or investment requirements.
Debt to Capital Ratio Analysis
The debt to capital ratio remained remarkably stable, fluctuating within a narrow range between 0.38 and 0.43. The ratio reached its maximum value of 0.43 in December 2024, coinciding with the sharpest increase in total debt. However, the ratio quickly reverted to a range of 0.41 to 0.42 for the remainder of the period. The alignment between the growth of total debt and total capital indicates that the organization maintained a consistent target for its long-term solvency and capital structure.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Debt to Assets

Elevance Health Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Short-term borrowings — — 724 150 180 360 250 365 360 225 1,575 225 — 265 265 265 265 175 275
Current portion of long-term debt 375 375 350 1,099 749 1,648 1,643 1,649 2,100 2,900 2,900 1,649 799 — — 1,500 2,249 2,248 3,097
Long-term debt, less current portion 30,382 30,669 30,768 30,797 31,173 28,178 28,110 29,218 24,688 24,561 21,976 23,246 24,045 24,859 25,201 22,349 21,258 21,165 19,883
Total debt 30,757 31,044 31,842 32,046 32,102 30,186 30,003 31,232 27,148 27,686 26,451 25,120 24,844 25,124 25,466 24,114 23,772 23,588 23,255
 
Total assets 127,801 126,438 125,827 121,494 122,749 121,938 119,717 116,889 116,533 112,988 111,894 108,928 110,478 109,168 109,040 102,772 103,026 100,877 100,486
Solvency Ratio
Debt to assets1 0.24 0.25 0.25 0.26 0.26 0.25 0.25 0.27 0.23 0.25 0.24 0.23 0.22 0.23 0.23 0.23 0.23 0.23 0.23
Benchmarks
Debt to Assets, Competitors2
Abbott Laboratories 0.29 0.30 0.31 0.15 0.15 0.16 0.16 0.17 0.20 0.20 0.20 0.20 0.22 0.23 0.23 0.23 0.23 0.23 0.23
Intuitive Surgical Inc. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Medtronic PLC 0.31 0.32 0.31 0.31 0.30 0.31 0.31 0.28 0.28 0.28 0.28 0.27 0.30 0.29 0.26 0.27 0.27 0.28 0.28
UnitedHealth Group Inc. 0.24 0.24 0.25 0.25 0.25 0.26 0.26 0.26 0.26 0.26 0.26 0.23 0.22 0.23 0.25 0.23 0.20 0.22 0.21

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= 30,757 ÷ 127,801 = 0.24

2 Click competitor name to see calculations.


The solvency profile of the organization remains stable over the analyzed period, characterized by a consistent balance between debt accumulation and asset growth. While both total debt and total assets increased, the leverage ratio remained within a narrow range, indicating a disciplined approach to capital structure management.

Total Debt Trends
Total debt exhibited a general upward trajectory, rising from 23,255 million USD in March 2022 to 30,757 million USD by September 2026. A notable increase occurred between September 2024 and December 2024, where debt rose from 27,148 million USD to 31,232 million USD. Following a peak of 32,102 million USD in September 2025, a gradual decline is observed through the end of the period.
Asset Growth Analysis
Total assets demonstrated steady and consistent growth, expanding from 100,486 million USD in March 2022 to 127,801 million USD in September 2026. This growth indicates a continuous expansion of the balance sheet, which served to offset the increase in total liabilities and maintain solvency levels.
Debt to Assets Ratio Dynamics
The debt to assets ratio remained remarkably stable for the first several quarters, holding at 0.23 from March 2022 through June 2023. A period of increased leverage began in 2024, reaching a peak ratio of 0.27 in December 2024. Subsequently, the ratio moderated and stabilized between 0.24 and 0.26 throughout 2025 and 2026, suggesting that the organization successfully aligned its debt levels with its asset base expansion.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Financial Leverage

Elevance Health Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Total assets 127,801 126,438 125,827 121,494 122,749 121,938 119,717 116,889 116,533 112,988 111,894 108,928 110,478 109,168 109,040 102,772 103,026 100,877 100,486
Shareholders’ equity 44,681 44,883 43,902 43,882 43,953 43,722 42,503 41,315 43,775 42,191 40,608 39,306 38,423 38,205 37,356 36,307 35,991 35,812 35,975
Solvency Ratio
Financial leverage1 2.86 2.82 2.87 2.77 2.79 2.79 2.82 2.83 2.66 2.68 2.76 2.77 2.88 2.86 2.92 2.83 2.86 2.82 2.79
Benchmarks
Financial Leverage, Competitors2
Abbott Laboratories 2.12 2.14 2.12 1.66 1.65 1.66 1.67 1.71 1.87 1.86 1.87 1.90 1.92 1.97 1.99 2.03 2.04 2.03 2.09
Intuitive Surgical Inc. 1.21 1.15 1.15 1.15 1.14 1.13 1.12 1.14 1.14 1.13 1.13 1.16 1.17 1.17 1.16 1.17 1.15 1.14 1.13
Medtronic PLC 1.87 1.88 1.90 1.91 1.82 1.86 1.87 1.79 1.75 1.75 1.77 1.77 1.83 1.80 1.71 1.73 1.75 1.76 1.78
UnitedHealth Group Inc. 3.19 3.15 3.19 3.29 3.29 3.26 3.26 3.22 3.17 3.20 3.28 3.08 3.34 3.40 3.49 3.16 3.26 3.16 3.04

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= 127,801 ÷ 44,681 = 2.86

2 Click competitor name to see calculations.


The organization demonstrated a consistent upward trajectory in total assets and shareholders' equity from March 2022 through September 2026, while maintaining a relatively stable financial leverage ratio. This suggests a disciplined approach to growth, where the expansion of the asset base was supported by a corresponding increase in the capital base.

Total Asset Expansion
Total assets grew from 100,486 million US dollars in March 2022 to 127,801 million US dollars by September 2026. The growth was characterized by a steady increase, with a more pronounced acceleration observed between March 2024 and September 2024, where assets rose from 111,894 million to 116,533 million US dollars.
Shareholders' Equity Development
Equity increased from 35,975 million US dollars in March 2022 to 44,681 million US dollars by September 2026. While the general trend was positive, a notable contraction occurred in December 2024, where equity dropped to 41,315 million US dollars from a previous high of 43,775 million US dollars in September 2024, before recovering in subsequent quarters.
Financial Leverage Stability
The financial leverage ratio fluctuated within a narrow corridor between 2.66 and 2.92. A peak in leverage was recorded in March 2023 at 2.92, followed by a downward trend that reached a minimum of 2.66 in September 2024. The ratio subsequently stabilized, ending the period at 2.86 in September 2026, indicating that the organization has maintained a consistent capital structure relative to its total assets.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Interest Coverage

Elevance Health Inc., interest coverage calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Shareholders’ net income 1,365 1,463 1,764 547 1,189 1,743 2,183 418 1,016 2,300 2,246 856 1,289 1,853 1,989 949 1,618 1,653 1,805
Add: Net income attributable to noncontrolling interest (22) (9) (4) (1) (2) 1 1 (5) (8) 1 3 (25) 11 3 15 12 (5) (3) (10)
Add: Income tax expense 451 483 544 (331) 219 548 613 193 365 685 690 170 354 585 615 193 533 493 531
Add: Interest expense 358 364 357 366 351 341 344 340 300 280 265 259 259 261 251 229 213 208 201
Earnings before interest and tax (EBIT) 2,152 2,301 2,661 581 1,757 2,633 3,141 946 1,673 3,266 3,204 1,260 1,913 2,702 2,870 1,383 2,359 2,351 2,527
Solvency Ratio
Interest coverage1 5.33 5.08 5.39 5.79 6.16 6.33 7.14 7.67 8.52 9.07 8.70 8.49 8.87 9.76 9.95 10.13 10.75 10.71 11.01
Benchmarks
Interest Coverage, Competitors2
Abbott Laboratories 7.59 10.81 16.18 18.17 16.99 15.90 14.40 13.55 12.65 11.74 11.46 11.46 10.79 11.34 13.06 15.89 18.41 20.07 18.10
Medtronic PLC 8.81 9.03 8.67 8.72 7.89 7.72 7.65 7.73 8.87 8.97 9.90 9.43 10.15 11.02 10.88 10.98 10.95 10.18 5.65
UnitedHealth Group Inc. 6.12 5.48 4.68 4.67 6.51 7.48 7.94 6.14 6.39 6.79 7.53 9.97 10.21 10.99 12.25 13.59 14.66 14.45 14.26

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Interest coverage = (EBITQ3 2026 + EBITQ2 2026 + EBITQ1 2026 + EBITQ4 2025) ÷ (Interest expenseQ3 2026 + Interest expenseQ2 2026 + Interest expenseQ1 2026 + Interest expenseQ4 2025)
= (2,152 + 2,301 + 2,661 + 581) ÷ (358 + 364 + 357 + 366) = 5.33

2 Click competitor name to see calculations.


An analysis of the interest coverage ratio reveals a sustained long-term decline from March 2022 through September 2026. The ratio decreased from a peak of 11.01 to 5.33, indicating a reduction in the margin of safety available to meet interest obligations from operating profits.

Earnings Before Interest and Tax (EBIT) Trends
EBIT exhibits significant quarterly volatility with a pronounced seasonal pattern. A recurring decline is observed every December, with the lowest point occurring in December 2025 at 581 million. Despite periodic peaks, such as the 3,266 million recorded in June 2024, the earnings profile demonstrates instability that contributes to fluctuations in solvency metrics.
Interest Expense Trajectory
A consistent upward trend in interest expenses is evident throughout the analyzed period. Expenses rose steadily from 201 million in March 2022 to 358 million by September 2026. This monotonic increase suggests an expansion of the debt load or an increase in the cost of servicing existing debt.
Interest Coverage Ratio Dynamics
The interest coverage ratio has undergone a steady contraction, driven by the combination of rising interest costs and inconsistent EBIT. The ratio remained relatively stable above 10.00 during 2022 but began a more accelerated decline after March 2023. The most significant erosion occurred between March 2024 and June 2026, during which the ratio fell from 8.70 to a period low of 5.08. While a marginal recovery to 5.33 was noted in the final quarter, the overall capacity to cover interest expenses has diminished substantially over the five-year window.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?